Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Impact of ocrelizumab on patient-reported fatigue and quality of life in relapsing multiple sclerosis patients treated for the first time with ocrelizumab (MoOzaRt): an observational study

Next Previous
Trial Profile

Impact of ocrelizumab on patient-reported fatigue and quality of life in relapsing multiple sclerosis patients treated for the first time with ocrelizumab (MoOzaRt): an observational study

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ocrelizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms NIS MoOzaRt
  • Sponsors Roche

Most Recent Events

  • 20 Dec 2023 Planned End Date changed from 28 Dec 2025 to 31 Mar 2026.
  • 13 Oct 2023 Trial design presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis
  • 13 Oct 2023 According to Trial design presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis, a first interim analysis of MoOzaRt will be presented, including 6- and 12-month-follow-up data of approximately 80-90 RMS patients. To date, 148 RMS patients have been recruited by 25 centres in Germany and Switzerland.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top